Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib | Zendy

Weibin Wang | Zendy; Helen H. Kang | Zendy; Yinu Zhao | Zendy; Irene M. Min | Zendy; Brian Wyrwas | Zendy; Maureen D. Moore | Zendy; Lisong Teng | Zendy; Rasa Zarnegar | Zendy; Xuejun Jiang | Zendy; Thomas J. Fahey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib

Author(s) -

Weibin Wang,

Helen H. Kang,

Yinu Zhao,

Irene M. Min,

Brian Wyrwas,

Maureen D. Moore,

Lisong Teng,

Rasa Zarnegar,

Xuejun Jiang,

Thomas J. Fahey

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-1999

Subject(s) - vemurafenib , autophagy , cancer research , thyroid cancer , mutant , cancer , medicine , anaplastic thyroid cancer , oncology , biology , melanoma , apoptosis , metastatic melanoma , biochemistry , gene

The RAF inhibitor vemurafenib has provided a major advance for the treatment of patients with BRAF-mutant metastatic melanoma. However, BRAF-mutant thyroid cancer is relatively resistant to vemurafenib, and the reason for this disparity remains unclear. Anticancer therapy-induced autophagy can trigger adaptive drug resistance in a variety of cancer types and treatments. To date, role of autophagy during BRAF inhibition in thyroid cancer remains unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research